FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer

Coverage, in order

1. 6d ago
   first FDA Drug Safety / Drugs feed indie

   FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer

   FDA granted accelerated approval to amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.

2. 3d ago
   FDA Drug Safety / Drugs feed indie

   FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma

   On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.

3. 11h ago
   FDA Drug Safety / Drugs feed indie

   FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer

   On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.